These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27322141)

  • 1. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.
    Posch C; Moslehi H; Sanlorenzo M; Green G; Vujic I; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
    Oncotarget; 2016 Jul; 7(29):45916-45925. PubMed ID: 27322141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Ponatinib as a Potent Agent against
    Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
    Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
    Todd JR; Becker TM; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Smalley KS; Sondak VK; Weber JS
    Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
    Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
    Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
    Liang R; Wallace AR; Schadendorf D; Rubin BP
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):714-23. PubMed ID: 21595858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT and Melanoma: Biological Insights and Clinical Implications.
    Pham DDM; Guhan S; Tsao H
    Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential role for nilotinib in KIT-mutated melanoma.
    Tran A; Tawbi HA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
    Meng D; Carvajal RD
    Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
    Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
    Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
    JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
    J Clin Invest; 2017 Nov; 127(11):4179-4192. PubMed ID: 29035277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
    Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
    J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plasma membrane Ca
    Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
    Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
    Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
    Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.
    Abu-Abed S; Pennell N; Petrella T; Wright F; Seth A; Hanna W
    J Cutan Med Surg; 2012; 16(2):135-42. PubMed ID: 22513068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.